Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and SBRT in neoadjuvant breast cancer
NCT07254858Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT07254858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254858.